Ifp Advisors, Inc Bio N Tech Se Transaction History

Ifp Advisors, Inc

$2.42 Billion
Q2 2024

A detailed history of Ifp Advisors, Inc transactions in Bio N Tech Se stock. As of the latest transaction made, Ifp Advisors, Inc holds 40 shares of BNTX stock, worth $4,914. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 40 -0.0%

Holding current value

$4,914

Previous $3,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 30, 2024	BUY	$88.96 - $112.35 $3,558 - $4,494	40 New	40 $3,000
Q1 2023 Apr 18, 2023	SELL	$122.57 - $153.67 $5,883 - $7,376	-48 Reduced 29.81%	113 $14,000
Q4 2022 Feb 07, 2023	SELL	$118.43 - $186.05 $3,434 - $5,395	-29 Reduced 15.26%	161 $4,000
Q3 2022 Nov 08, 2022	BUY	$127.65 - $183.11 $3,191 - $4,577	25 Added 15.15%	190 $6,000
Q2 2022 Sep 06, 2022	BUY	$123.25 - $186.24 $20,336 - $30,729	165 New	165 $5,000
Q2 2022 Aug 12, 2022	SELL	$123.25 - $186.24 $20,336 - $30,729	-165 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$126.25 - $231.85 $6,565 - $12,056	52 Added 46.02%	165 $28,000
Q3 2021 Oct 06, 2021	SELL	$205.93 - $447.23 $21,828 - $47,406	-106 Reduced 48.4%	113 $31,000
Q2 2021 Jul 13, 2021	BUY	$113.32 - $241.49 $3,059 - $6,520	27 Added 14.06%	219 $49,000
Q1 2021 Apr 30, 2021	SELL	$85.73 - $119.5 $6,258 - $8,723	-73 Reduced 27.55%	192 $20,000
Q4 2020 Jan 25, 2021	SELL	$72.71 - $129.54 $10,106 - $18,006	-139 Reduced 34.41%	265 $22,000
Q3 2020 Oct 29, 2020	BUY	$57.81 - $104.17 $11,793 - $21,250	204 Added 102.0%	404 $27,000
Q1 2020 May 12, 2020	BUY	$28.55 - $92.0 $5,710 - $18,400	200 New	200 $11,000

Others Institutions Holding BNTX

# of Institutions

356

Shares Held

38.3M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account